Clinical Trials Browser

Phase 2 × Interventional × ipatasertib × Clear all

NCT05172258 2026-03-18

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT05554380 2026-03-18

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

Phase 2 Suspended

Neoplasm Metastasis

NCT05564377 2026-03-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT04931342 2026-03-10

BOUQUET

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT04589845 2026-03-06

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Phase 2 Recruiting

920 enrolled 1 FDA

Other solid neoplasm

Solid Tumors

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Phase 2 Recruiting

Breast Neoplasms

NCT05498896 2025-03-10

BARBICAN

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

Phase 2 Completed

Neoplasm Metastasis

NCT04464174 2024-07-26

PATHFINDER

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT03395899 2024-06-18

ECLIPSE

Phase 2 Completed

Breast Neoplasms

NCT04467801 2023-11-07

Ipat-Lung

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT01896531 2022-03-02

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Phase 2 Completed

153 enrolled 16 charts

Gastrointestinal

Stomach Neoplasms

NCT04739202 2021-03-29

IMMUNOGAST

Phase 2 Unknown

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT04561817 2020-10-06

To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase 2 Withdrawn

Ovarian Neoplasms, Recurrence

NCT02301988 2018-10-17

A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer

Phase 2 Completed

151 enrolled 22 charts

Breast Neoplasms